---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-006042"
form_type: "8-K"
ticker: "SGMT"
cik: "0001400118"
company_name: "Sagimet Biosciences Inc."
filed_at: "2024-01-24T23:59:59+00:00"
generated_at: "2026-06-06T19:10:32.130754+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Sagimet Biosciences reports preliminary cash of $94.9M as of Dec 31, 2023

## Summary
- Cash, cash equivalents and short-term investments estimated at ~$94.9M.
- Amount is unaudited, prepared by management and subject to completion of closing procedures.
- Actual year-end 2023 results may differ; will be included in Form 10-K.

## SEC filing metadata
- accession: 0001104659-24-006042
- form_type: 8-K
- ticker: SGMT
- cik: 0001400118
- company_name: Sagimet Biosciences Inc.
- filed_at: 2024-01-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1400118/000110465924006042/0001104659-24-006042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1400118/000110465924006042/tm2333216d9_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-006042
- JSON: https://secwatch.observer/filing/0001104659-24-006042.json
- Plain text: https://secwatch.observer/filing/0001104659-24-006042.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.